title: Pancolitis a novel early complication of Alemtuzumab for MS treatment.
abstract: The growing range of effective therapies for relapsing remitting multiple sclerosis (RRMS) brings with it a wider range of possible complications requiring broader considerations and greater vigilance. Alemtuzumab is a humanized monoclonal antibody against CD52 that is highly effective in the treatment of RRMS and approved in many countries around the world. We describe a case presenting with a complication not previously seen.
authors.affiliation: Neurosciences, The Alfred, Melbourne, Victoria 3004, Australia. Electronic address: nirosenv@gmail.com.
authors.forename: Nirosen
authors.initials: N
authors.lastname: Vijiaratnam
authors.affiliation: Neurosciences, The Alfred, Melbourne, Victoria 3004, Australia. Electronic address: L.Rath@alfred.org.au.
authors.forename: Louise
authors.initials: L
authors.lastname: Rath
authors.affiliation: Neurosciences, The Alfred, Melbourne, Victoria 3004, Australia. Electronic address: sansxu@gmail.com.
authors.forename: San San
authors.initials: SS
authors.lastname: Xu
authors.affiliation: Neurosciences, The Alfred, Melbourne, Victoria 3004, Australia. Electronic address: o.skibina@alfred.org.au.
authors.forename: Olga
authors.initials: O
authors.lastname: Skibina
mesh_terms: D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D003092:Colitis / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications* / Q000188:drug therapy*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000074323:Alemtuzumab
keywords: Alemtuzumab; Complications; Infections; Multiple sclerosis